Eric Dessertenne, directeur général de BIOCORP, reviendra sur les récentes annonces de partenariats autour des dispositifs médicaux connectés développés par l’entreprise.
Les prochains mois devraient être riches en nouveaux catalyseurs pour BIOCORP notamment autour de la montée en puissance commerciale de Mallya, soutenue par un flot permanent d’innovations et de services visant à améliorer le quotidien des patients.
Le management d’Adocia reviendra sur les dernières avancées cliniques de ses programmes BC Lispro, BC Combo, M1Pram et exposera les perspectives très prometteuses de la technologie AdoShell, un biomatériau qui pourrait transformer le traitement du diabète par thérapie cellulaire.
Advicenne est une société française pharmaceutique, spécialisée dans le développement de traitements innovants en néphrologie. Son médicament principal, Sibnayal® a reçu en 2021 une autorisation de mise sur le marché en Europe et au Royaume-Uni dans le traitement de l’acidose tubulaire rénale distale (ATRd). Il est en cours de commercialisation sur plusieurs territoires en propre mais également à travers plusieurs partenariats de distribution. ADV7103 est actuellement en phase avancée de développement clinique aux Etats-Unis et au Canada dans l’ATRd et dans la cystinurie en Europe et aux Etats-Unis.
En parallèle, Advicenne commercialise également Likozam et Ledvicen dans les formes rares de l’épilepsie et dispose d’une seconde AMM en Europe avec Ozalin®, produit licencié au Suisse Primex. Basée à Paris, l’entreprise est cotée sur le marché Euronext Growth à Paris.
Pixium Vision est une société française en phase de pré-commercialisation qui développe une solution de vision bionique, le Système Prima, pour les personnes ayant perdu la vue en raison d’une dégénérescence maculaire sèche liée à l’âge (DMLA sèche). Elle est la principale source de cécité avec une large population de patients (plus de 8 millions dans le monde) avec des besoins médicaux importants non satisfaits : aucun traitement ou solution sur le marché ! Le Système Prima fait actuellement l’objet d’études pivots de phase 3 sur l’homme.
Accounts of meetings with industry leaders and specialists, interviews, webinars, training modules, on-line access to company data, publications, for:
• Follow innovations in health and life sciences (Biotech, Medtech, Diagnostics, E-health, Big Data, Cleantech, Silver Economy).
• Understand the specificities of the sector
• Understand the positioning and potential of companies
Private meetings with leaders and those who make the news in biotechs.
Networking: Leaders, professionals in the healthcare industry, health professionals, researchers, institutions, consultants, fundraisers, business angels, family offices, fund managers, venture capitalists , …
Biotech Agora successfully resumed the concept of privileged encounters between individual investors passionate about the health sector and leaders of biotechnology companies. Participants are of high quality and aware of the innovations of the different actors. The formula combines conviviality and personalized relationships in an exclusive setting. In summary, a very good springboard to become better acquainted with individual shareholders particularly active in our field.
I very much appreciated the meeting organized by Biotech Agora and the discussions with the people present at the event.
The format, format and quality of the assistance lent itself very well to presentation and discussion.
This type of meeting has a very positive and pedagogical impact: it helps to maintain a link with investors who are very demanding in order to better understand the achievements and prospects of the company. It was also an opportunity to meet new investors who were not familiar with Cerenis and who were passionate about the subject.
Biotech Agora helps to disseminate objective information. This is important in the current context where a lot of misinformation can easily circulate on networks and forums to maintain a direct link with individual investors.
The format of Biotech Agora evenings with a one and a half hour conference followed by a cocktail to continue the discussions in a more informal setting is very appropriate to better understand and deepen the complex subjects.
Too often the topics are overflown and potential shareholders and investors do not always find the answers to their questions.
The presentation made by the company's CEO provides a better understanding of the project's stakes, its strengths in relation to competition, and the various phases of development in which the project fits.
The assistance of investors is enriched by the presence of biotech specialists (analysts, journalists ...) who bring a pedagogical, didactic side and raise the debates. The accessibility and the quality of the exchanges are made possible by the assistance limited to about sixty people.
I attended the Biotech Agora Cerenis evening. The presentation was brilliant, with no double talk. No false pretenses. Very good evening. To renew. Do not change anything to the setting of it.
These meetings of leaders in small committees are for me a privileged place of exchange outside the Shareholers’meetings. It also allows me to discover new and beautiful companies to which I would not necessarily have thought and appreciate their potential.
Contacts with other investors also allow to share points of view outside the forums that I do not frequent, and this, for their lack of reliability.